BMYMP Stock Bristol-Myers Squibb (BMYMP, $900) RSI Indicator left the overbought zone on December 15, 2025

GET DAILY SIGNALS

Get AI intraday signals

BMYMP - Bristol-Myers Squibb Co.

RSI signal

View

Odds of DOWN Trend

Price: $900

Daily change: +$18.89 (+2.14%)

Daily volume: 43

Industry: Pharmaceuticals: Major

This is a signal that BMYMP's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. A.I.dvisor looked back and found 28 similar cases where BMYMP's RSI Indicator left the overbought zone, and in of them led to a successful outcome. Odds of Success:

BMYMP's Stochastic Oscillator is staying in overbought zone for 20 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for BMYMP moved out of overbought territory on December 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for BMYMP turned negative on December 22, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

BMYMP broke above its upper Bollinger Band on November 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMYMP advanced for three days, in of 17 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 119 cases where BMYMP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (9.054). BMYMP has a moderately low P/E Ratio (0.000) as compared to the industry average of (24.434). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.056). BMYMP has a moderately low Dividend Yield (0.002) as compared to the industry average of (0.026). BMYMP's P/S Ratio (0.000) is slightly lower than the industry average of (3.759).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMYMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMYMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.